[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Honda M, Baba H, Yonekura M, Iseki M: Cerebral composite atypical teratoid/rhabdoid tumor and yolk sac tumor in the frontal lobe of an infant. Case report. Neurol Med Chir (Tokyo); 2005 Jun;45(6):318-21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral composite atypical teratoid/rhabdoid tumor and yolk sac tumor in the frontal lobe of an infant. Case report.
  • A 1-year-old male infant presented with a rare cerebral composite tumor consisting of atypical teratoid/rhabdoid tumor (AT/RT) with epithelial and mesenchymal components and yolk sac tumor (YST) with Schiller-Duval bodies.
  • Computed tomography and magnetic resonance imaging revealed a large, intra-axial solid tumor with a cyst in the left frontal lobe.
  • Total resection of the tumor was performed.
  • Initial total resection of the tumor was subsequently followed by local recurrence, hydrocephalus, and spinal metastasis.
  • Despite adjuvant chemotherapy, the patient died 9 months after admission.
  • The present case of composite AT/RT and YST in the frontal lobe indicates the poor prognosis of such tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Endodermal Sinus Tumor / pathology. Frontal Lobe / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973067.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Lamborn KR, Chang SM, Prados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol; 2004 Jul;6(3):227-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival for patients with glioblastoma multiforme is short, and current treatments provide limited benefit.
  • Therefore, there is interest in conducting phase 2 trials of experimental treatments in newly diagnosed patients.
  • However, this requires historical data with which to compare the experimental therapies.
  • In this retrospective study of 832 glioblastoma multiforme patients enrolled into prospective clinical trials at the time of initial diagnosis, we evaluated several potential prognostic markers for survival to establish risk groups.
  • Initially, patients from 8 clinical trials, 6 of which included adjuvant chemotherapy, were included.
  • Subsequent analyses excluded trials with interstitial brachytherapy, and finally included only nonbrachytherapy trials with planned adjuvant chemotherapy.
  • The 2 lower risk groups included patients under the age of 40, the lowest risk group being young patients with tumor in the frontal lobe only.
  • Subgroup analyses indicated that inclusion of adjuvant chemotherapy provides an increase in survival, although that improvement tends to be minimal for patients over age 65, for patients over age 40 with KPS less than 80, and for those treated with brachytherapy.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2002 Jan 30;21(2):313-26 [11782067.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neurosurgery. 2002 Aug;51(2):343-55; discussion 355-7 [12182772.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Stat Med. 1993 Dec 30;12(24):2351-66 [8134738.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11 [9719109.001]
  • (PMID = 15279715.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA82103; United States / NINDS NIH HHS / NS / NS42927; United States / NCI NIH HHS / CA / P30 CA082103; United States / NCI NIH HHS / CA / P50 CA097257; United States / NINDS NIH HHS / NS / P01 NS042927; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / CA13525
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1871999
  •  go-up   go-down


3. Barut F, Kandemir NO, Ozdamar SO, Gul S, Bektas S, Gun BD, Bahadir B: Gliosarcoma with chondroblastic osteosarcomatous differentation: report of two case with clinicopathologic and immunohistochemical features. Turk Neurosurg; 2009 Oct;19(4):417-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliosarcoma is a rare tumor of the central nervous system characterized by a biphasic histological pattern.
  • The case had radiotherapy and chemotherapy postoperatively.
  • After the first operation, additional resections were performed for tumor because of recurrences at the fourth, seventh and tenth months.
  • The patient died after the last tumor resection.
  • Histopathologic examination of the postmortem biopsy revealed neoplasm displaying a biphasic morphologic pattern including both gliomatous and sarcomatous components.
  • CASE 2: The case was a 69-year-old male patient with a right frontal lobe mass histologically diagnosed as gliosarcoma displaying sarcomatous and glial components.
  • We report two cases with an extremely rare histopathological diagnosis of "gliosarcoma with features of chondroblastic osteosarcoma".
  • [MeSH-major] Brain Neoplasms / pathology. Chondroblastoma / pathology. Gliosarcoma / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Aged. Biopsy. Cell Differentiation. Ependymoma / pathology. Ependymoma / surgery. Fatal Outcome. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847765.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


Advertisement
4. Tsuchiya D, Kayama T, Kuchiki H, Sato S, Saito S: [A case of olfactory neuroblastoma with intracranial extension and distant metastasis]. No To Shinkei; 2000 Sep;52(9):811-6
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Olfactory neuroblastoma is a rare tumor originating in the upper nasal cavity.
  • MRI showed a huge mass that occupied the right nasal and paranasal cavities, and extended into the right frontal base.
  • The tumor was removed totally and was histologically diagnosed as olfactory neuroblastoma.
  • About two months after surgery, however, MRI demonstrated a rapid recurrence of the tumor in the nasal and paranasal cavities and the frontal lobe.
  • Chemotherapy was administered using cisplatin and etoposide.
  • The tumor in the frontal lobe shrunk markedly but the other lesion persisted.
  • Whole brain irradiation and local irradiation of the cervical lymph nodes were performed.
  • Olfactory neuroblastoma is a slow-growing tumor and is highly radiosensitive, but it rarely extends or develops multiple distant metastases and seldom shows a short survival time, as in our case.
  • A review of the literature documented responses in patients treated with a cisplatin-based drug combination.
  • We recommend systemic control using cisplatin-based chemotherapy in addition to irradiation to prevent local recurrence in cases of advanced or metastatic olfactory neuroblastoma.
  • [MeSH-minor] Adult. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064869.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


5. Jahraus CD, Friedman AH: Chemopotentiation by ultrafractionated radiotherapy in glioblastoma resistant to conventional therapy. Tumori; 2010 Sep-Oct;96(5):771-5
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopotentiation by ultrafractionated radiotherapy in glioblastoma resistant to conventional therapy.
  • CASE AND METHODS: The case of an 82-year-old woman is described whose resected frontoparietal glioblastoma progressed through treatment administered according to standard methods.
  • With review board and patient approval, we continued her treatment using radiotherapy and temozolomide, but drastically modified the radiotherapy fractionation, administering 50 cGy twice daily on each of the first 5 days of a 14-day cycle.
  • RESULTS: This modified regimen resulted in regression of the contrast-enhancing areas of disease recurrence identified on MRI, and the patient survived approximately 6 months following recurrence of her disease, having received 5 cycles of additional therapy after prior full-dose treatment.
  • CONCLUSIONS: Ultrafractionated radiotherapy and concurrent temozolomide were efficacious and tolerable in this patient whose glioblastoma previously progressed through conventional treatment.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Dose Fractionation. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Aged, 80 and over. Disease Progression. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Magnetic Resonance Imaging. Temporal Lobe / pathology. Temporal Lobe / surgery. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302627.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


6. Sasayama T, Mizukawa K, Sakagami Y, Mizowaki T, Tanaka K, Ohbayashi C, Mori K, Kitazawa S, Kohmura E: Glioblastoma multiforme associated with klinefelter syndrome. Neurol Med Chir (Tokyo); 2009 Nov;49(11):532-5
MedlinePlus Health Information. consumer health - Klinefelter's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging showed multiple heterogeneously enhanced tumors in the bilateral frontal lobes.
  • Angiography showed no tumor stain or arteriovenous shunt.
  • The tumor was partially removed through a right craniotomy.
  • The histological diagnosis was glioblastoma.
  • Postoperative local radiotherapy (60 Gy/30 fractions) combined with temozolomide (75 mg/m(2) x 42 days) and interferon-beta (3,000,000 U, 3 times/week) was performed.
  • The patient's clinical status rapidly deteriorated during chemoradiotherapy, and he died of tumor progression 3.5 months after the surgery.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioblastoma / genetics. Glioblastoma / pathology. Klinefelter Syndrome / complications. Klinefelter Syndrome / genetics
  • [MeSH-minor] Basal Ganglia / pathology. Craniotomy. Disease Progression. Drug Therapy. Fatal Outcome. Frontal Lobe / pathology. Frontal Lobe / surgery. Genetic Predisposition to Disease / genetics. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Neurosurgical Procedures. Paraparesis / etiology. Radiotherapy. Thalamus / pathology. Treatment Failure

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Klinefelter syndrome.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19940404.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Kurosaki M, Taniura S, Tanaka S, Takenobu A, Watanabe T, Horie Y: Gliosarcoma associated with a huge cyst--case report. Neurol Med Chir (Tokyo); 2000 Nov;40(11):581-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography demonstrated a large cyst in the right frontal lobe, and enhancement of the mural nodule after administration of contrast medium.
  • Xanthochromic fluid was aspirated, and the tumor was resected.
  • The histological diagnosis was gliosarcoma based on the presence of gliomatous and sarcomatous components.
  • She underwent a second operation because of tumor regrowth 3 weeks after the first operation.
  • The postoperative course was satisfactory during radiation therapy with 60 Gy and chemotherapy.
  • The diagnosis of gliosarcoma was difficult to make preoperatively because of the neuroradiological findings similar to low-grade gliomas.
  • Gliosarcoma should be included in the differential diagnosis of huge cystic tumors.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / diagnosis. Cysts / complications. Cysts / diagnosis. Frontal Lobe. Gliosarcoma / complications. Gliosarcoma / diagnosis
  • [MeSH-minor] Brain Diseases / complications. Brain Diseases / diagnosis. Craniotomy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gliosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109796.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


8. Godard J, Viennet G, Raul JS, Plouvier E, Miny J, Jacquet G, Czorny A: [Intramedullary spread of a cerebral oligodendroglioma. Two case reports]. Neurochirurgie; 2000 Dec;46(6):558-562
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis was suspected on MRI but imaging findings were nonspecific.
  • In the reported cases, both frontal and cystic primary intracerebral lesions were observed.
  • Chemotherapy after radiotherapy appears to improve outcome.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe. Oligodendroglioma / secondary. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Abducens Nerve Diseases / etiology. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carmustine / therapeutic use. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Paralysis / etiology. Prognosis. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11148408.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


9. Ducray F, Colin P, Cartalat-Carel S, Pelissou-Guyotat I, Mahla K, Audra P, Gaucherand P, Honnorat J, Trouillas P: [Management of malignant gliomas diagnosed during pregnancy]. Rev Neurol (Paris); 2006 Mar;162(3):322-9
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prise en charge des gliomes malins découverts au cours d'une grossesse.
  • In post-partum additional treatment with chemotherapy was started.
  • In post-partum additional treatment with radiotherapy and chemotherapy was started.
  • MRI showed a left frontal lesion.
  • Two weeks after surgery the patient's neurological condition worsened and in agreement with the patient a therapeutic abortion was decided.
  • Afterwards additional treatment with radiotherapy and chemotherapy was started.
  • The last patient received combined treatment with radiotherapy and chemotherapy for local recurrence of a mesencephalic high-grade glioma.
  • A posteriori it was discovered that the patient was at 4 months' gestation during this treatment.
  • Their pregnancy should not prevent them from receiving the best treatment for their glioma.
  • Treatment will depend upon clinico-radiological presentation, histology, gestational age and the patient's desires.
  • After the first trimester of gestation this treatment can be given without any important risks for the child.
  • [MeSH-major] Case Management. Glioblastoma / therapy. Pregnancy Complications, Neoplastic / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Abortion, Therapeutic. Adrenal Cortex Hormones / therapeutic use. Adult. Algorithms. Anesthesia, General. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carbamazepine / therapeutic use. Carmustine / administration & dosage. Cesarean Section. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Frontal Lobe. Humans. Infant, Newborn. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Paresis / drug therapy. Paresis / etiology. Prednisolone / therapeutic use. Pregnancy. Prenatal Exposure Delayed Effects. Radiotherapy, Adjuvant. Remission Induction. Temporal Lobe

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Neurol (Paris). 2006 Mar;162(3):293-4 [16585883.001]
  • (PMID = 16585887.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 33CM23913M / Carbamazepine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9PHQ9Y1OLM / Prednisolone; GQ7JL9P5I2 / fotemustine; U68WG3173Y / Carmustine
  •  go-up   go-down


10. Koeller KK, Rushing EJ: From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation. Radiographics; 2005 Nov-Dec;25(6):1669-88
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oligodendroglioma is the third most common glial neoplasm and most commonly arises in the frontal lobe.
  • The clinical presentation is often of several years duration with most patients presenting with seizures, reflecting the strong predilection of this tumor to involve the cortical gray matter.
  • Current histopathologic classification schemes recognize two main types of tumors: well-differentiated oligodendroglioma and its anaplastic variant.
  • Surgical resection is the mainstay of initial treatment, and many patients experience a long progression-free period.
  • Recent genotyping has revealed chromosomal loss of 1p and 19q as a genetic signature in most oligodendrogliomas, and these tumors respond favorably to chemotherapy.
  • Hence, radiation therapy is now generally reserved for partially resected tumors and cases that failed to benefit from chemotherapy.
  • At cross-sectional imaging, the tumor characteristically involves the cortical gray matter and frequently contains calcification.
  • [MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Prognosis. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284142.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 140
  •  go-up   go-down


11. MacRae R, Grimard L, Hsu E, Nizalik E, Halton JM: Brain metastases in Wilms' tumor: case report and literature review. J Pediatr Hematol Oncol; 2002 Feb;24(2):149-53
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases in Wilms' tumor: case report and literature review.
  • A 2-year-old girl who had a stage 2, favorable-histology Wilms tumor diagnosed when she was age 10 months presented with multiple brain metastases at second recurrence.
  • She had been treated with combined radiotherapy, surgery, and chemotherapy; at 2 months after treatment, recurrent disease developed in the central nervous system and she died.
  • Brain metastases are rare in the natural history of Wilms tumor.
  • Although it does not appear that cerebral metastases are a barrier to tumor eradication and long-term survival if treated with combined modality therapy, treatment should be individualized.
  • [MeSH-major] Brain Neoplasms / secondary. Frontal Lobe. Kidney Neoplasms. Occipital Lobe. Parietal Lobe. Wilms Tumor / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Craniotomy. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Infant. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / surgery. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Nephrectomy. Palliative Care. Paresis / etiology. Thoracotomy

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11990704.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 25
  •  go-up   go-down


12. Gorelick J, Ross D, Marentette L, Blaivas M: Sinonasal undifferentiated carcinoma: case series and review of the literature. Neurosurgery; 2000 Sep;47(3):750-4; discussion 754-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SNUC tends to present with advanced-stage disease, often with intracranial invasion, and requires an aggressive treatment approach that includes surgical resection.
  • INTERVENTION: All four patients underwent multimodal treatment with chemotherapy, radiotherapy (60-65 Gy), and aggressive surgical resection via a combined bifrontal craniotomy and a subcranial approach to the anterior cranial fossa.
  • Three of four patients died as a result of their disease, an average of 15 months after diagnosis.
  • Only one patient remains alive, although with metastatic intracranial disease, at 24 months after diagnosis.
  • CONCLUSION: SNUC is a rare neoplasm with a poor prognosis despite an aggressive multimodal approach to treatment.
  • On the basis of our experience, we advocate radical resection as part of the initial combined therapy for patients who present with locally advanced, nonmetastatic disease but we suggest reserving surgery for patients with early brain invasion until there has been a radiographically proven central nervous system response to adjuvant therapy.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10981763.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 16
  •  go-up   go-down


13. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg; 2004 Mar;100(3):472-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.
  • OBJECT: A minority of patients with recurrent glioblastomas multiforme (GBMs) responds to systemic chemotherapy.
  • The patients were observed daily by performing diffusion-weighted (DW) magnetic resonance (MR) imaging to assess the convective process and routine diagnostic MR imaging to identify the tumor response.
  • Effective convection was determined by the progression of the hyperintense signal within the tumor on DW MR images, which corresponded to a subsequent lytic tumor response displayed on conventional MR images.
  • The antitumor effect was confirmed by one biopsy and three en bloc resections of tumors, which showed a complete response, and by one tumor resection, which demonstrated a partial response.
  • Lack of convection and a poor tumor response was associated with leakage of the convected drug into the subarachnoid space, ventricles, and cavities formed by previous resections, and was seen in tumors containing widespread necrosis.
  • CONCLUSIONS: On the basis of our data we suggest that CED of paclitaxel in patients with recurrent malignant gliomas is associated with a high antitumor response rate, although it is associated with a significant incidence of treatment-associated complications.
  • Diffusion-weighted MR images may be used to predict a response by demonstrating the extent of convection during treatment.
  • Optimization of this therapeutic approach to enhance its efficacy and reduce its toxicity should be explored further.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Convection. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Diffusion Magnetic Resonance Imaging. Dose-Response Relationship, Drug. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Glioblastoma / drug therapy. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Male. Middle Aged. Parietal Lobe / pathology. Parietal Lobe / surgery. Prospective Studies. Temporal Lobe / pathology. Temporal Lobe / surgery

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15035283.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Tong-tong W, Li-juan B, Zhi L, Yang L, Bo-ning L, Quan H: Clear cell meningioma with anaplastic features: case report and review of literature. Pathol Res Pract; 2010 May 15;206(5):349-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first case is a 65-year-old male who gradually developed changes in behavior over a period of 1 year.
  • Magnetic resonance imaging revealed an intracranial lesion in the right frontal lobe in the male patient, and an intradural extramedullary lesion at C7 in the female patient.
  • Tumor cells were immunoreactive to epithelial membrane antigen (EMA) and vimentin, with a high MIB-1 index up to 40%.
  • The male patient was found to have developed local recurrence and lateral ventricle metastasis 3 months after surgery.
  • A diagnosis of CCM with anaplastic features was made (WHO grade III).
  • Based on its aggressive behavior, we recommend postoperative adjuvant radiotherapy or chemotherapy even if total excision of the tumor has been performed, and MRI scans every 3-6 months during the first period of follow-up.
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Anaplasia / pathology. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier GmbH. All rights reserved.
  • (PMID = 19857933.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Shima H, Nishizaki T, Ishihara H, Moroi J, Fujii M, Suzuki M: Recurrent intracranial germinoma with dissemination along the ventricular catheter: a case report. J Clin Neurosci; 2002 Nov;9(6):708-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recurrent tumor, verified histologically as a pure germinoma, involved the right frontal lobe along the ventricular catheter.
  • In spite of subsequent surgery, radiation and chemotherapy, the tumor recurred repeatedly.
  • We also discuss possible causes of tumor dissemination along the ventricular catheter.
  • [MeSH-major] Brain Neoplasms / pathology. Germinoma / pathology. Neoplasm Recurrence, Local / pathology. Ventriculoperitoneal Shunt
  • [MeSH-minor] Adult. Catheters, Indwelling / adverse effects. Humans. Magnetic Resonance Imaging. Male. Time Factors

  • Genetic Alliance. consumer health - Germinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Published by Elsevier Science Ltd.
  • (PMID = 12604292.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


16. Sasani M, Oktenoglu T, Ozer AF, Sarioglu AC: Giant supratentorial atypical teratoid/rhabdoid tumor presentation: a case of a five-year-old child with favorable outcome and review of the literature. Pediatr Neurosurg; 2007;43(2):149-54
Genetic Alliance. consumer health - Rhabdoid tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant supratentorial atypical teratoid/rhabdoid tumor presentation: a case of a five-year-old child with favorable outcome and review of the literature.
  • Atypical teratoid/rhabdoid tumor of the central nervous system is a highly malignant neoplasm and that usually arises in the posterior fossa, survival from this is frequently poor.
  • We present a unique case in a 21-month-old girl who had an atypical teratoid/rhabdoid tumor with cystic components located in the right fronto-parietal lobe.
  • The patient underwent radical surgical intervention followed by chemotherapy.
  • Two years later at the last follow-up visit, there was no evidence of a tumor relapse on MRI, and the examination was symptom free.
  • It is possible the favorable outcome of the patient resulted from a rapid diagnosis, prompt management, radical surgical intervention and aggressive chemotherapy.
  • [MeSH-major] Frontal Lobe / surgery. Parietal Lobe / surgery. Rhabdoid Tumor / surgery. Supratentorial Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Actins / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / analysis. Humans. Infant. Keratins / analysis. Magnetic Resonance Imaging. Microsurgery. Mitotic Index. Necrosis. Neurologic Examination. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17337931.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 14
  •  go-up   go-down


17. Hammond RR, Duggal N, Woulfe JM, Girvin JP: Malignant transformation of a dysembryoplastic neuroepithelial tumor. Case report. J Neurosurg; 2000 Apr;92(4):722-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a dysembryoplastic neuroepithelial tumor. Case report.
  • Computerized tomography (CT) scanning revealed a superficial hypodense nonenhancing lesion in the midleft frontal convexity, with some remodeling of the overlying skull.
  • He received no chemotherapy or radiation therapy and remained well for 11 years.
  • A Grade IV astrocytoma was resected, and within the malignant tumor was a superficial area reminiscent of a dysembryoplastic neuroepithelial tumor (DNT).
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Frontal Lobe / pathology. Glioblastoma / pathology. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adult. Astrocytoma / pathology. Electroencephalography. Epilepsies, Partial / diagnosis. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / pathology. Neuroglia / pathology. Neurons / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761668.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S, Hayashi K, Iwaki T, Sasaki T: Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy. Neurol Res; 2007 Oct;29(7):723-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy.
  • OBJECTIVE AND IMPORTANCE: Oligodendroglial tumors rarely occur after radiation therapy.
  • Here, we report a rare case of anaplastic oligodendroglioma arising after radiation therapy, in which genetic analysis was performed.
  • CLINICAL PRESENTATION AND INTERVENTION: A 41-year-old man who had received radiation therapy for a tumor of the suprasellar and pineal regions 31 years previously, presented with headache and progressive right hemiparesis.
  • Magnetic resonance (MR) images revealed a ring-enhanced mass lesion in the left frontal lobe.
  • Total removal of the tumor was performed through left frontoparietal craniotomy, and the histologic diagnosis was anaplastic oligodendroglioma.
  • Based on the genetic analysis, this tumor was considered to be sensitive to chemotherapy.
  • Two courses of chemotherapy, with procarbazine, ACNU and vincristine, were performed.
  • However, tumor recurrence was detected only 3 months after the surgery.
  • Despite additional radiochemotherapy, the tumor aggressively increased in size and the patient died with multiple recurrent tumors 1 year after surgery.
  • [MeSH-major] Brain Neoplasms / genetics. Cell Transformation, Neoplastic / genetics. Frontal Lobe / pathology. Loss of Heterozygosity / genetics. Neoplasms, Radiation-Induced / genetics. Oligodendroglioma / genetics. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 19 / genetics. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Microsatellite Repeats / genetics. Neoplasm Recurrence, Local. Predictive Value of Tests. Treatment Failure


19. Schmid I, Stachel D, Graubner UB, Elsner R, Schulze S, Pöllinger B, Goetz C, Haas RJ: [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature]. Klin Padiatr; 2005 May-Jun;217(3):153-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature].
  • [Transliterated title] Supratentorieller primitiver neuroektodermaler Tumor: Erfahrungen in einem Zentrum im Vergleich zur Literatur.
  • All had craniospinal irradiation and chemotherapy according to the HIT-91 protocol.
  • The two children with incomplete resection died due to tumor progression after 7 and 10 months.
  • Two of the 4 children with complete tumor resection had local relapses 8 months after diagnosis and died after 14 and 18 months.
  • One child had a diffuse meningeal relapse 12 months after diagnosis.
  • Despite (high-dose) systemic chemotherapy and intraventricular mafosfamide, he died 21 months after diagnosis due to tumor although remission could be achieved.
  • Only one child is still in remission 86 months after diagnosis.
  • [MeSH-major] Brain Neoplasms. Cerebellar Nuclei. Corpus Callosum. Frontal Lobe. Neuroectodermal Tumors. Occipital Lobe. Parietal Lobe. Temporal Lobe. Thalamus
  • [MeSH-minor] Brain Stem Neoplasms / secondary. Cerebellar Neoplasms / mortality. Cerebellar Neoplasms / surgery. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Humans. Male. Mesencephalon. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858707.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Shimato S, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D, Hasegawa Y, Hyodo I, Nagasaka T, Yoshida J: Brain metastases from apocrine carcinoma of the scalp: case report. J Neurooncol; 2006 May;77(3):285-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from apocrine carcinoma of the scalp: case report.
  • Apocrine carcinoma is an extremely rare malignant neoplasm that occurs most frequently in the axilla.
  • However, a literature search did not reveal any report describing the detailed clinical course of brain metastases from apocrine carcinoma.
  • We report a case of a 54-year-old male who suffered from multiple brain metastases from apocrine carcinoma that had originated in the scalp 6 years before.
  • The brain metastases appeared in spite of several regimens of chemotherapy for lung metastases for two years.
  • The tumor in the right frontal lobe was successfully operated.
  • However, the small tumor in the right occipital lobe was not cured by gamma knife surgery, and eventually required second operation.
  • To our knowledge this is the first reported case of metastatic brain tumor from apocrine carcinoma.
  • [MeSH-major] Apocrine Glands / pathology. Brain Neoplasms / secondary. Carcinoma / secondary. Lung Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Male. Middle Aged. Occipital Lobe / pathology. Occipital Lobe / surgery. Scalp / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cutan Pathol. 1984 Oct;11(5):437-49 [6096425.001]
  • [Cites] Am J Clin Oncol. 1999 Apr;22(2):131-5 [10199445.001]
  • [Cites] Pathol Annu. 1987;22 Pt 1:83-124 [3033589.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 1989;23(2):157-8 [2814387.001]
  • [Cites] Am J Dermatopathol. 1998 Aug;20(4):389-92 [9700379.001]
  • [Cites] Tumori. 2000 Nov-Dec;86(6):472-4 [11218189.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1986;3(1):29-34 [2422504.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 1):566-9 [15056154.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):375-81 [7678545.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):832-6 [8037297.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):515-24 [12507088.001]
  • [Cites] Arch Dermatol. 1978 Feb;114(2):198-203 [629545.001]
  • [Cites] J Am Acad Dermatol. 1979 Dec;1(6):545-56 [528703.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1276-81 [12507123.001]
  • [Cites] Dermatology. 1999;199(4):332-7 [10640844.001]
  • (PMID = 16314948.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Baker MJ, Brem S, Daniels S, Sherman B, Phuphanich S: Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J Neurooncol; 2002 Sep;59(3):239-42
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite its biological activity in vitro, there have not been any prior reports of efficacy in the treatment of human malignant gliomas.
  • The patient initially presented with seizures caused by a biopsy-proven anaplastic astrocytoma of the frontal lobe.
  • The patient was treated with radiation therapy and Procarbazine-CCNU-Vincristine (PCV).
  • However, the tumor progressed and extended to the corpus callosum with midline shift, refractory to four cycles of continuous 72-h infusion of BCNU/Cisplatinum.
  • Additional enhancing lesions appeared in the left frontal and left temporal lobes.
  • Phenylbutyrate is a well-tolerated, oral agent that shows potential for the treatment of malignant gliomas.
  • Further studies should be considered to identify a subset of patients that have tumors sensitive to phenylbutyrate, either as a single agent or in combination with radiation therapy or other chemotherapeutic agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Phenylbutyrates / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Lomustine / therapeutic use. Magnetic Resonance Imaging. Procarbazine / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2004 Jan;66(1-2):251; author reply 251 [15015793.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):891-5 [8313377.001]
  • [Cites] Adv Exp Med Biol. 1997;400A:501-5 [9547596.001]
  • [Cites] Cancer Control. 1998 Mar;5(2):107-114 [10761021.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):681-92 [10690554.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3541-50 [11848521.001]
  • [Cites] Mayo Clin Proc. 1999 Feb;74(2):137-45 [10069350.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):984-90 [10071293.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1755-62 [9815560.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):97-108 [9524087.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Cancer Control. 1999 Oct;6(5):436-458 [10758576.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2932-8 [7773944.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2923-7 [8187079.001]
  • (PMID = 12241121.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1 CA 76614
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phenylbutyrates; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7WY7YBI87E / 4-phenylbutyric acid; PCV protocol
  •  go-up   go-down


22. Prayson RA, Abramovich CM: Glioneuronal tumor with neuropil-like islands. Hum Pathol; 2000 Nov;31(11):1435-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioneuronal tumor with neuropil-like islands.
  • Recently, an unusual glioneuronal tumor arising in adults marked histologically by neuropil-like islands was described.
  • We present a similar case arising in a 23-year-old woman who presented with headaches and seizures and on imaging studies was noted to have a frontal-temporal lobe mass.
  • The patient underwent partial resection of the tumor, which histologically resembled anaplastic astrocytoma, and received a course of radiation therapy and chemotherapy.
  • Increasing seizure frequency and expanding size on neuroimaging prompted a re-excision of the tumor.
  • The second resection was marked by islands of tissue resembling gray matter with slightly atypical neuronal and glial cells situated in the white matter.
  • Mild vascular proliferation and moderate nuclear pleomorphism also characterized the tumor.
  • P53 immunoreactivity was observed in approximately 40% of tumor cell nuclei.
  • This lesion is felt to represent a clinically aggressive glioneuronal neoplasm with an unusual and distinctive histologic phenotype.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Neuropil / pathology
  • [MeSH-minor] Adult. Antigens, Nuclear. Cell Nucleus / chemistry. Cell Nucleus / pathology. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen. Neovascularization, Pathologic / pathology. Nuclear Proteins / analysis. Reoperation. Synaptophysin / analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 by W.B. Saunders Company
  • (PMID = 11112223.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / Synaptophysin; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Chen CS, Miller NR, Lane A, Eberhart C: Third cranial nerve palsy caused by intracranial extension of a sino-orbital natural killer T-cell lymphoma. J Neuroophthalmol; 2008 Mar;28(1):31-5
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 53-year-old man with systemic lupus erythematosus who was receiving chronic low-dose prednisone treatment developed proptosis of the right eye.
  • Clinical and imaging manifestations resolved with a higher dose of prednisone, but when the prednisone dose was tapered, the patient developed a complete right third cranial nerve palsy.
  • Biopsy of this lesion in its early stage may misleadingly suggest a primary inflammatory disorder because of a paucity of neoplastic cells, a large number of inflammatory cells recruited by the innate natural killer (NK) cell immune response, and extensive necrosis caused by angiodestructive tumor cells.
  • [MeSH-major] Frontal Lobe / pathology. Lymphoma, Extranodal NK-T-Cell / complications. Lymphoma, Extranodal NK-T-Cell / diagnosis. Oculomotor Nerve Diseases / etiology. Oculomotor Nerve Diseases / pathology. Orbit / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Antigens, Neoplasm / analysis. Antigens, Neoplasm / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / immunology. Fatal Outcome. Humans. Immunosuppressive Agents / therapeutic use. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Oculomotor Nerve / pathology. Oculomotor Nerve / physiopathology. Prednisone / therapeutic use. Radiotherapy. Tomography, X-Ray Computed. Treatment Failure

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347456.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Immunosuppressive Agents; VB0R961HZT / Prednisone
  •  go-up   go-down


24. Engelhard HH: Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol; 2000 Mar;53(3):220-4
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor bed cyst formation after BCNU wafer implantation: report of two cases.
  • The purpose of this report is to alert neurosurgeons to an additional potential side effect: formation of a cystic mass within the implanted tumor bed.
  • CASE PRESENTATIONS: Two patients are described: a 54-year-old male, who presented with a large right parieto-occipital mass, and a 47-year-old woman with a large right frontal lobe tumor.
  • Both tumors were found on initial craniotomy to be glioblastoma multiforme; both recurred rapidly despite radiation therapy.
  • Patients were treated with a second craniotomy for tumor resection and placement of BCNU wafers.
  • After implantation, the first patient did well for 6 weeks, then developed lethargy, headaches, and vomiting.
  • In each case, minimal tumor and no evidence of infection were found.
  • CONCLUSIONS: The hypodense, roughly spherical cysts clearly demonstrated clinically significant mass effect, and required reoperation despite treatment with high-dose corticosteroids.
  • Neurosurgeons should be alert to the possibility of tumor bed cyst formation in patients treated with interstitial BCNU wafers.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Brain Diseases / chemically induced. Brain Neoplasms / drug therapy. Carmustine / adverse effects. Cysts / chemically induced. Glioblastoma / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Implants. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiography

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10773252.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Drug Implants; U68WG3173Y / Carmustine
  •  go-up   go-down


25. Lee EJ, Chang CH, Wang LC, Hung YC, Chen HH: Two primary brain tumors, meningioma and glioblastoma multiforme, in opposite hemispheres of the same patient. J Clin Neurosci; 2002 Sep;9(5):589-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two primary brain tumors, meningioma and glioblastoma multiforme, in opposite hemispheres of the same patient.
  • We report a case with double primary intracranial tumors of different cell types without phacomatosis.
  • Initial computed tomographic (CT) examinations revealed a large hyperdense tumor over the right frontal lobe, suggestive of an extra-axial meningioma.
  • Additionally, there was unusual brain edema in the contralateral hemisphere that subsequently proved to originate from an intrinsic tumor.
  • The patient made an uneventful recovery after treatment.
  • We suggest that extraordinary brain edema far remote from the primary brain lesion warrants special attention for identifying other potentially undetected lesions.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Meningioma / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Female. Functional Laterality / physiology. Humans. Neoplasm Recurrence, Local. Seizures / drug therapy. Seizures / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12383424.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


26. McGirt MJ, Villavicencio AT, Bulsara KR, Friedman HS, Friedman AH: Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. J Neurosurg; 2002 May;96(5):941-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.
  • Adjuvant use of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafers with surgical resection is becoming common for the treatment of malignant gliomas.
  • Cyst formation in the tumor resection cavity is a recently described complication associated with the use of BCNU wafers.
  • The authors describe four patients in whom postoperative cysts developed in the tumor resection cavity after placement of BCNU wafers.
  • These include a 38-year-old man with a left frontoparietal tumor, a 48-year-old man with a right frontal lobe tumor, a 78-year-old man with a left parietooccipital tumor, and a 61-year-old woman with a left frontotemporal tumor.
  • The fourth patient improved after surgical drainage and biopsy sampling of the cyst, which revealed no evidence of infection or recurrent tumor, but again sought medical care 2 weeks later with cyst recurrence necessitating high-dose steroid therapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Carmustine / adverse effects. Cysts / drug therapy
  • [MeSH-minor] Adult. Aged. Anti-Inflammatory Agents / administration & dosage. Biopsy. Brain / pathology. Brain / surgery. Chemotherapy, Adjuvant. Dexamethasone / administration & dosage. Drainage. Drug Implants. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications / chemically induced. Postoperative Complications / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12005403.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Drug Implants; 7S5I7G3JQL / Dexamethasone; U68WG3173Y / Carmustine
  •  go-up   go-down


27. Takagi Y, Nakamura H, Miwa K, Adachi Y, Fujioka S, Haruki T, Taniguchi Y: A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy. Thorac Cardiovasc Surg; 2010 Aug;58(5):304-6
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy.
  • A very small nodule was noted in the right frontal lobe on brain MRI before surgery, and the final diagnosis was pT3N0M1, stage IV lung adenocarcinoma.
  • For the brain metastasis, gamma knife treatment and chemotherapy were performed after surgery, and there was no recurrence during 16 months after surgery.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / blood. Lung Neoplasms / therapy. Lymph Node Excision. Pneumonectomy
  • [MeSH-minor] Biopsy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Neurosurgical Procedures. Positron-Emission Tomography. Radiotherapy, Adjuvant. Thoracic Wall / pathology. Thoracic Wall / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 20680910.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


28. Li JP, Yin XL, Kong PY, Chen XH, Zeng DF, Xiang XX, Peng XG: [Intracerebral infiltration by monoclonal plasmacytoid cells in Waldenstrom's macroglobulinemia: a case report and review of the literature]. Zhonghua Xue Ye Xue Za Zhi; 2009 Oct;30(10):672-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To sum up the clinical experience of the diagnosis and treatment of intracerebral infiltration by monoclonal plasmacytoid cells in Waldenstrom's macroglobulinemia(Bing-Neel syndrome).
  • METHODS: The clinical data of the diagnosis and treatment of a case of Bing-Neel syndrome was analyzed.
  • RESULTS: A 56-year-old male was diagnosed as Waldenstrom's macroglobulinemia one year ago, and presented with persistent headache during the treatment period.
  • Magnetic resonance imaging showed a high intensity area on T2-weighed images in the right frontal lobe which was well enhanced by gadolinium-diethylenetriaminepenta-acetic acid.
  • As there is no effective therapy for this Bing-Neel syndrome, combination of radiation and chemotherapy should be considered for this situation.
  • [MeSH-major] Brain / pathology. Waldenstrom Macroglobulinemia / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954662.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


29. Watanabe K, Arai A, Takase H, Takahashi H, Iwanaga Y, Sugamoto Y, Sugita S, Mochizuki M, Miura O: [Primary intraocular lymphoma invaded to the central nervous system after successful treatment with intraocular methotrexate injection]. Rinsho Ketsueki; 2009 Mar;50(3):182-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intraocular lymphoma invaded to the central nervous system after successful treatment with intraocular methotrexate injection].
  • Although cytological examinations of the vitreous samples revealed Class II, the diagnosis of primary intraocular lymphoma (PIOL) was made by detecting both IgH rearrangement by PCR and an elevated ratio of IL-10/IL-6 concentration in the vitreous sample.
  • Open biopsy was performed and a diagnosis of diffuse large B-cell lymphoma was made.
  • Diagnosis of PIOL is difficult.
  • Since local treatment was considered insufficient, an optimal treatment strategy for PIOL should be established.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Eye Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Methotrexate / administration & dosage. Vitreous Body
  • [MeSH-minor] Fatal Outcome. Frontal Lobe. Humans. Injections, Intralesional. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352085.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


30. Deshmukh P, Glick RP, Lichtor T, Moser R, Cohen EP: Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice. J Neurosurg; 2001 Feb;94(2):287-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice.
  • Brain metastases occur in 15 to 30% of patients with breast cancer, and this usually results in death.
  • Despite the availability of surgery, radiotherapy, and chemotherapy, the prognosis for patients with breast cancer that has metastasized to the intracerebral region remains poor.
  • This study was designed to determine if an intracerebrally metastasizing breast tumor could be treated successfully with a cellular vaccine consisting of allogeneic fibroblasts (H-2K) modified to secrete interleukin (IL)-2.
  • METHODS: The authors used EO771 breast cancer cells, derived from a spontaneously arising breast-cancer tumor in C57BL/6 mice.
  • The authors first determined the length of survival of C57BL/6 mice that had been injected with varying numbers of EO771 cells into the right frontal lobes and found that 100% of those animals that received a dose of 10(4) cells died within 41 days, whereas 100% of the group that received 10(3) cells died within 23 days.
  • Based on these results, 5 x 10(4) EO771 cells were injected into the right frontal lobe of C57BL/6 mice and the animals were treated intracerebrally with a single intratumoral injection of 10(6) allogeneic fibroblasts genetically engineered to secrete IL-2.
  • The effects of this treatment on the animal's survival and the tumor's histopathological characteristics were investigated.
  • Tumor did not develop in four of 10 animals in the IL-2-treated group, and these animals were rechallenged at 90 days by intracerebral injection of tumor, but no treatment cells, and compared with four naive animals receiving intracerebral tumor.
  • Again, animals that previously had been treated with IL-2-secreting fibroblasts had a markedly prolonged survival (p < 0.05) compared with control animals following a second challenge with tumor cells.
  • CONCLUSIONS: This work represents a new treatment for breast cancer that has metastasized to the brain in which a cellular vaccine consisting of allogeneic fibroblasts genetically engineered to secrete cytokines is used as a novel means for delivery of immunogene therapy and demonstrates the induction of long-term immunity against tumor.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / secondary. Brain Neoplasms / secondary. Fibroblasts / immunology. Genetic Therapy. Interleukin-2 / genetics. Mammary Neoplasms, Experimental / immunology
  • [MeSH-minor] Animals. Brain / pathology. Female. Humans. Mice. Mice, Inbred C57BL. Neoplasm Transplantation. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11213967.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2
  •  go-up   go-down


31. Nataf F, Koziak M, Ricci AC, Varlet P, Devaux B, Beuvon F, Roujeau T, Page P, Cioloca C, Turak B, Schlienger M, Touboul E, Haie-Meder C, Vannetzel JM, Dhermain F, Honnorat J, Jouvet A, De Saint-Pierre G, Daumas-Duport C, Bret P, Roux FX: [Results of the Sainte-Anne - Lyons series of 318 oligodendroglioma in adults]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):329-51
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied a homogeneous series using the Sainte-Anne grading scale in order to better understanding the history of these tumors with or without treatment and to assess prognosis and associated factors.
  • For grade A: age at diagnosis ranged from 21 to 70 (mean: 41), sex ratio was 1.28.
  • For grade B: age at diagnosis ranged from 12 to 75 (mean: 45.5), sex-ratio was 1.58.
  • The most frequent locations were: frontal, insular and central for both A and B.
  • No tumor was enhanced on imaging (CT/MRI) in grade A, all but 7 in grade B.
  • Chemotherapy was delivered for 36% of grade A (in the event of transformation to grade B or failure of radiotherapy) and 67.5% of B patients.
  • In univariate and multivariate analysis, grade A survival was associated with age at diagnosis, tumor size, large removal and response to radiotherapy.
  • Grade B survival was associated with age at diagnosis, wide removal and sharply defined limits of the tumor on imaging.
  • Treatment should consequently progress towards more targeted procedures for patients mainly with postoperative radiotherapy and chemotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Staging / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Epilepsy / diagnosis. Epilepsy / etiology. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292177.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Koga T, Morita A, Maruyama K, Tanaka M, Ino Y, Shibahara J, Louis DN, Reifenberger G, Itami J, Hara R, Saito N, Todo T: Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. Neuro Oncol; 2009 Aug;11(4):446-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytic neoplasm of the brain.
  • No previous reports have demonstrated consistent efficacy of adjuvant radiotherapy or chemotherapy for this disease.
  • A 47-year-old woman presented with an epileptic seizure due to a large tumor in the right frontal lobe.
  • The tumor was resected and diagnosed as PXA with anaplastic features.
  • Two years later, the patient developed a tumor nodule in the cervical spinal cord that histologically corresponded to a small-cell glioma with high cellularity and prominent MIB-1 (mindbomb homolog 1) labeling.
  • In the following months, multiple nodular lesions appeared throughout the CNS, and STI was performed six times for eight intracranial lesions using Gamma Knife and twice using a linear accelerator, for three spinal cord lesions in total.
  • However, diffuse dissemination along the craniospinal axis eventually progressed, and she died 66 months after initial diagnosis.
  • Autopsy showed that the nodules remained well demarcated from the surrounding nervous system tissue.
  • STI may be an effective therapeutic tool for controlling nodular dissemination of PXA with anaplastic features.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 1999 Oct;13(5):516-9 [10627788.001]
  • [Cites] Histopathology. 2008 Jan;52(2):183-93 [18184267.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):563-6 [11585332.001]
  • [Cites] Ultrastruct Pathol. 2001 Nov-Dec;25(6):469-78 [11783911.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Dec;61(12):1092-9 [12484572.001]
  • [Cites] Childs Nerv Syst. 2004 Feb;20(2):119-22 [14669022.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] Neurosurgery. 1985 May;16(5):703-6 [4000446.001]
  • [Cites] Neurosurgery. 1988 Feb;22(2):422-7 [3352896.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):463-8 [2644402.001]
  • [Cites] Acta Neuropathol. 1989;78(6):585-93 [2816300.001]
  • [Cites] Clin Neuropathol. 1993 Mar-Apr;12(2):97-101 [8477554.001]
  • [Cites] Acta Neuropathol. 1994;87(3):225-32 [8009954.001]
  • [Cites] Neurosurg Rev. 1996;19(1):13-6 [8738360.001]
  • [Cites] Acta Neuropathol. 1996;91(3):293-7 [8834542.001]
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):50-6 [9083703.001]
  • [Cites] J Neurosurg Sci. 1998 Sep;42(3):153-7 [10192056.001]
  • [Cites] Cancer. 1999 May 1;85(9):2033-45 [10223246.001]
  • [Cites] Acta Neurochir (Wien). 2006 Jan;148(1):67-71; discussion 71 [15912255.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4):674-85; discussion 674-85 [16575331.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):1081-9; discussion 1081-9 [16723887.001]
  • [Cites] J Neurol Sci. 2007 Jan 31;252(2):144-53 [17189643.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):1088-97 [16909113.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):184-92 [11465399.001]
  • (PMID = 19164434.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2743225
  •  go-up   go-down


33. Cheong JH, Kim CH, Kim JM, Oh YH: Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report. Clin Neurol Neurosurg; 2010 Oct;112(8):701-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report.
  • Gliosarcoma is an uncommon malignant brain tumor composed of distinct sarcomatous and malignant glial cell elements.
  • These tumors are defined as a variant of glioblastoma, and it can be developed by progression of the malignant glial cell tumors or primary tumors.
  • We report a rare case with gliosarcomatous recurrence of anaplastic astrocytoma with neurofibromatosis type 1 (NF-1) followed by chemoradiation therapy.
  • Magnetic resonance imaging (MRI) showed a well-demarcated, enhanced lesion in the right frontal lobe and multiple enhanced lesions in the scalp, lower cervical, thoracic, and upper lumbar regions.
  • He underwent an osteoplastic craniotomy with total tumor resection.
  • Histopathology of the tumor showed findings corresponding with anaplastic astrocytoma.
  • He was followed by radiotherapy and chemotherapy postoperatively.
  • The subsequent follow-up period of 27 months was uneventful until he developed a generalized tonic-clonic seizure.
  • MRI showed tumor recurrence in the original site of the tumor.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Neurofibromatosis 1 / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / pathology. Follow-Up Studies. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Gliosarcoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20466481.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ: Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol; 2009 Dec;11(6):737-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have shown that the clinical outcome of anaplastic oligodendroglial tumors is variable, but also that the histological diagnosis is subject to interobserver variation.
  • We investigated whether the assessment of 1p/19q codeletion, polysomy of chromosome 7, epidermal growth factor receptor (EGFR) gene amplification (EGFR(amp)), and loss of chromosome 10 or 10q offers additional prognostic information to the histological diagnosis and would allow molecular subtyping.
  • For this study, we used the clinical data and tumor samples of the patients included in multicenter prospective phase III European Organisation for Research and Treatment of Cancer (EORTC) study 26951 on the effects of adjuvant procarbazine, chloroethyl cyclohexylnitrosourea (lomustine), and vincristine chemotherapy in anaplastic oligodendroglial tumors.
  • Three different analyses were performed: on all included patients based on local pathology diagnosis, on the patients with confirmed anaplastic oligodendroglial tumors on central pathology review, and on this latter group but after excluding anaplastic oligoastrocytoma (AOA) with necrosis.
  • In 257 of 368 patients, central pathology review confirmed the presence of an anaplastic oligodendroglial tumor.
  • Tumors with combined 1p and 19q loss (1p(loss)19q(loss)) were histopathologically diagnosed as anaplastic oligodendroglioma, were more frequently located in the frontal lobe, and had a better outcome.
  • Anaplastic oligodendroglial tumors with EGFR(amp) were more frequently AOA, were more often localized outside the frontal lobe, and had a survival similar to that for GBM.
  • In univariate analyses, all molecular factors except loss of 10q were of prognostic significance, but on multivariate analysis a histopathological diagnosis of AOA, necrosis, and 1p(loss)19q(loss) remained independent prognostic factors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2000 May;119(1):42-7 [10812170.001]
  • [Cites] Neuropathology. 2008 Aug;28(4):440-3 [18312547.001]
  • [Cites] J Pathol. 2001 May;194(1):81-7 [11329145.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6713-5 [11559541.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jun;58(6):606-12 [10374751.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2318-26 [15470710.001]
  • [Cites] Neurology. 2004 Dec 28;63(12):2360-2 [15623700.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):695-703 [15936158.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):75-82 [16794749.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2499-503 [16914310.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51 [17549014.001]
  • [Cites] J Neurooncol. 2007 Sep;84(3):279-86 [17431544.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2097-108 [17934521.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):360-9 [18371182.001]
  • [Cites] Neuro Oncol. 2000 Jul;2(3):164-73 [11302337.001]
  • (PMID = 19224764.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 2U10CA11488-25; United States / NCI NIH HHS / CA / 2U10CA11488-35
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  • [Other-IDs] NLM/ PMC2802394
  •  go-up   go-down


35. Zigouris A, Pahatouridis D, Mihos E, Alexiou GA, Nesseris J, Zikou AK, Argyropoulou MI, Goussia A, Voulgaris S: Solitary cystic cerebral metastasis from transitional cell carcinoma of the bladder. Acta Neurol Belg; 2009 Dec;109(4):322-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic brain tumors are the most common intracranial neoplasm in adults.
  • Bladder cancer gives metastasis to the brain in less than 1%.
  • Brain imaging work-up revealed a cystic lesion with perifocal edema in the right frontal lobe.
  • The patient was operated and the histological diagnosis was consistent with a metastatic carcinoma, with morphological, histochemical and immunohistochemical features comparable to those of the primary tumor.
  • Postoperative the patient was in excellent neurological state and received complementary chemotherapy and total brain irradiation.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Cystectomy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120215.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


36. Iun'pén V, Oliushin VE, Ulitin AIu, Maslova LN, Petrov AA: [Long-term results of treatment in patients with oligodendrogliomas and oligoastrocytomas of the cerebral hemispheres]. Zh Vopr Neirokhir Im N N Burdenko; 2008 Apr-Jun;(2):6-10; discussion 10-1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of treatment in patients with oligodendrogliomas and oligoastrocytomas of the cerebral hemispheres].
  • BACKGROUND: the current approach to treating patients with cerebral oligodendrogliomas and oligoastrocytomas involves surgical treatment with the maximum tumor resection in reasonable ranges, by taking into account the anatomic and physiological availability, followed by chemo- and radiotherapy.
  • Nevertheless, it should be recognized that criteria for choosing the optimum regiment for the treatment of these tumors have not conclusively established.
  • MATERIALS: the long-term results of treatment were analyzed in 80 patients with oligoglial tumors (oligodendrogliomas and oligoastrocytomas in 31 and 49 patients, respectively) treated at the A.L.
  • 38.5% of tumors were located in the frontal lobe.
  • Radiotherapy was used in the treatment of 71 patients and postoperative chemotherapy in 52 (87,5%) patients.
  • RESULTS: After complex therapy, the mean survival was 80.6 months in patients with oligodendrogliomas, 63.3 months in those with anaplastic oligoastrocytomas, and 42 months in those with anaplastic oligodendrogliomas.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18720725.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


37. Shimizu J, Matsumoto M, Yamazaki E, Yasue M: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo); 2008 May;48(5):227-30
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain computed tomography incidentally revealed a left frontal lobe tumor measuring 5 cm in a diameter.
  • The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy.
  • The tumor was seen as an isointense lesion on T(1)-weighted magnetic resonance (MR) images with enhancement by gadolinium, and as a heterogeneously hyperintense mass on T(2)-weighted MR images.
  • The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane.
  • The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation.
  • Computed tomography and MR imaging performed at this time revealed remarkable regression of the tumor.
  • The signal intensity change with regression of the tumor on T(2)-weighted images was observed as a hypointense lesion.
  • Thus, we wish to emphasize that treatment of meningiomas, especially those diagnosed incidentally, must be based on a thorough consideration of any history of hormonal therapy with prostate disease.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Chlormadinone Acetate / administration & dosage. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Regression, Spontaneous
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Progesterone / agonists. Prostatic Hyperplasia / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0SY050L61N / Chlormadinone Acetate; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


38. Padula GD, McCormick B, Abramson DH: Brain necrosis after enucleation, external beam cobalt radiotherapy, and systemic chemotherapy for retinoblastoma. Arch Ophthalmol; 2002 Jan;120(1):98-9
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain necrosis after enucleation, external beam cobalt radiotherapy, and systemic chemotherapy for retinoblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cobalt Radioisotopes / adverse effects. Encephalomalacia / etiology. Eye Enucleation. Frontal Lobe / radiation effects. Radiation Injuries / etiology. Retinal Neoplasms / therapy. Retinoblastoma / therapy
  • [MeSH-minor] Child, Preschool. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Necrosis. Neoplasm Recurrence, Local / therapy. Orbital Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11786070.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


39. Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF, Oncodiagosis panel, 2002 RSNA Scientific Assembly: Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess. Radiographics; 2003 Nov-Dec;23(6):1591-611
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess.
  • [MeSH-major] Brain Abscess / diagnosis. Brain Neoplasms / diagnosis. Cysts / diagnosis. Frontal Lobe. Magnetic Resonance Imaging. Parietal Lobe
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy. Diagnosis, Differential. Fatal Outcome. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Male. Middle Aged. Quinazolines / therapeutic use. Radiotherapy, Adjuvant. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14635616.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down






Advertisement